BRAF V600E is associated with higher incidence of second cancers in adults with Langerhans cell histiocytosis.
Aldo A Acosta-MedinaPaul Geraeds KempsTimo Ce ZondagJithma P AbeykoonJelske Forma-BorstEline Christine SteenwijkElizabeth Arnoldina Maria FeijenJop C TeepenN Nora BennaniSusan M SchramMithun Vinod ShahCaroline Davidge-PittsMatthew J KosterJay H RyuRobert VassalloWilliam Oliver TobinJason R YoungSurendra DasariKaren L RechAishwarya RavindranArjen Hg ClevenRobert M VerdijkCarel J M van NoeselBrian V BalgobindGerrit J BoumaPeerooz SaeedJos A M BramerRuben Al de GroenJoost S P VermaatMichiel Adreanus van de SandeEgbert F SmitAnton W LangerakJ Tom van WezelSanne H ToninoCor van den BosJan A M van LaarRonald S GoGaurav GoyalAstrid G S van HalterenPublished in: Blood (2023)
In this retrospective study, BRAFmutation status did not correlate with disease extent or (event-free) survival in 156 adults with LCH. BRAFV600E was associated with an increased incidence of second malignancies, often comprising hematological cancers - which may be clonally related.